UniQure Stock Soars 234% On Positive Huntington's Disease Trial Data

(RTTNews) - uniQure N.V. (QURE) shares skyrocketed 234.17 percent to $45.80 on Wednesday, jumping $32.14, after the company reported positive topline results from its pivotal Phase I of II study of AMT-130 for the treatment of Huntington's disease.

The stock opened at $39.20 and traded between $37.12 and $47.37, compared with a prior close of $13.66 on the Nasdaq.

Trading volume surged to 42.0 million shares, far exceeding the average of 1.1 million. uniQure now trades within a 52-week range of $4.45 to $47.37, touching the top of its range.

The trial met its primary endpoint, with high-dose AMT-130 showing a statistically significant slowing of disease progression at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale, compared with matched external controls.